AFP and hepatocellular carcinoma: The novel HCC biomarker panel showed better performance than AFP at the clinical cutoff value of 20 ng/mL [31], which had a sensitivity of 52.2% (95% CI 43.5–60.7%) with 93.7% (95% CI 87.9–96.5%) specificity (Table 3).